KalVista Pharmaceuticals (KALV) Stock Forecast, Price Target & Predictions
KALV Stock Forecast
KalVista Pharmaceuticals stock forecast is as follows: an average price target of $26.00 (represents a 146.21% upside from KALV’s last price of $10.56) and a rating consensus of 'Buy', based on 4 wall street analysts offering a 1-year stock forecast.
KALV Price Target
The average price target for KalVista Pharmaceuticals (KALV) is $26.00 based on 1-year price targets from 4 Wall Street analysts in the past 3 months, with a price target range of $38.00 to $20.00. This represents a potential 146.21% upside from KALV's last price of $10.56.
KALV Analyst Ratings
According to 4 Wall Street analysts, KalVista Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for KALV stock is 0 'Strong Buy' (0.00%), 4 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
KalVista Pharmaceuticals Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 06, 2024 | Andrew Fein | H.C. Wainwright | $20.00 | $12.87 | 55.40% | 89.39% |
| Sep 06, 2024 | Joseph Schwartz | Leerink Partners | $20.00 | $12.87 | 55.40% | 89.39% |
| Jul 08, 2022 | - | Needham | $38.00 | $10.98 | 246.08% | 259.85% |
The latest KalVista Pharmaceuticals stock forecast, released on Sep 06, 2024 by Andrew Fein from H.C. Wainwright, set a price target of $20.00, which represents a 55.40% increase from the stock price at the time of the forecast ($12.87), and a 89.39% increase from KALV last price ($10.56).
KalVista Pharmaceuticals Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 2 | 2 | 2 |
| Avg Price Target | $20.00 | $20.00 | $20.00 |
| Last Closing Price | $10.56 | $10.56 | $10.56 |
| Upside/Downside | 89.39% | 89.39% | 89.39% |
In the current month, the average price target of KalVista Pharmaceuticals stock is $20.00, according to 2 Wall Street analysts offering twelve months forecast. The average price target represents a 89.39% increase as opposed to KalVista Pharmaceuticals's last price of $10.56. This month's average price target is down 0.00% compared to last quarter, and down 0.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 06, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 06, 2024 | Leerink Partners | Outperform | Outperform | Hold |
| Feb 03, 2023 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 08, 2022 | SVB Leerink | Outperform | Outperform | Hold |
| Jul 08, 2022 | Needham | Buy | Buy | Hold |
KalVista Pharmaceuticals's last stock rating was published by H.C. Wainwright on Sep 06, 2024. The company gave KALV a "Buy" rating, the same as its previous rate.
KalVista Pharmaceuticals Financial Forecast
KalVista Pharmaceuticals Revenue Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Jul 22 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Oct 19 | Jul 19 | Apr 19 | Jan 19 | Oct 18 | Apr 18 | Jan 18 | Oct 17 | Jul 16 | Apr 16 | Oct 15 | Jul 15 | Apr 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | $3.82M | $1.58M | $3.92M | $3.37M | $2.93M | $3.89M | $5.59M | $4.84M | $2.33M | $1.13M | - | - | - | - | - |
| Avg Forecast | $28.34M | $17.00M | $11.34M | - | $4.90M | $2.37M | $518.00K | - | $4.46M | - | $8.35K | $420.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $2.61M | $618.16K | $1.02M | $115.69K | $8.93K | $7.40K | $13.53K | $5.39K | $266.76K |
| High Forecast | $28.34M | $17.00M | $11.34M | - | $4.90M | $2.37M | $518.00K | - | $4.46M | - | $10.02K | $504.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $3.13M | $741.79K | $1.22M | $138.82K | $10.71K | $8.88K | $16.24K | $6.47K | $320.12K |
| Low Forecast | $28.34M | $17.00M | $11.34M | - | $4.90M | $2.37M | $518.00K | - | $4.46M | - | $6.68K | $336.00K | $1.20M | $625.00K | $1.50M | $1.90M | $10.08M | $3.27M | $3.22M | $4.03M | $4.25M | $2.09M | $494.53K | $813.60K | $92.55K | $7.14K | $5.92K | $10.83K | $4.31K | $213.41K |
| # Analysts | 1 | 1 | - | - | - | 2 | 1 | - | - | 1 | 15 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 9 | 12 | 17 | 9 | 8 | 15 | 15 | 19 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.02% | 0.16% | 1.20% | 1.05% | 0.73% | 0.91% | 2.14% | 7.83% | 2.29% | 9.74% | - | - | - | - | - |
KalVista Pharmaceuticals's average Quarter revenue forecast for Jul 20 based on 7 analysts is $1.50M, with a low forecast of $1.50M, and a high forecast of $1.50M. KALV's average Quarter revenue forecast represents a -60.77% decrease compared to the company's last Quarter revenue of $3.82M (Apr 20).
KalVista Pharmaceuticals EBITDA Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Jul 22 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Oct 19 | Jul 19 | Apr 19 | Jan 19 | Oct 18 | Apr 18 | Jan 18 | Oct 17 | Jul 16 | Apr 16 | Oct 15 | Jul 15 | Apr 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | 2 | 1 | - | - | 1 | 15 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 9 | 12 | 17 | 9 | 8 | 15 | 15 | 19 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-29.03M | $-25.64M | $-18.03M | $-12.82M | $-12.62M | $-14.75M | $-8.35M | $-12.58M | $-9.59M | $-8.85M | $-11.10M | $-6.80M | $-4.56M | $-3.18M | $-2.41M | $-5.97M | - | - | - | - | - |
| Avg Forecast | $5.67M | $3.40M | $2.27M | - | $979.20K | $473.52K | $103.60K | - | $892.05K | - | $-6.05M | $-13.87M | $-14.82M | $-14.08M | $-300.00K | $-9.91M | $-7.90M | $-9.36M | $-644.20K | $-5.16M | $-4.38M | $-3.15M | $-8.25M | $-4.39M | $-5.56M | $-6.47M | $-4.21M | $-6.13M | $-6.18M | $-164.52M |
| High Forecast | $5.67M | $3.40M | $2.27M | - | $979.20K | $473.52K | $103.60K | - | $892.05K | - | $-4.84M | $-11.10M | $-11.85M | $-11.26M | $-300.00K | $-7.93M | $-6.32M | $-7.49M | $-644.20K | $-4.13M | $-3.51M | $-2.52M | $-6.60M | $-3.51M | $-4.45M | $-5.17M | $-3.37M | $-4.91M | $-4.95M | $-131.61M |
| Low Forecast | $5.67M | $3.40M | $2.27M | - | $979.20K | $473.52K | $103.60K | - | $892.05K | - | $-7.26M | $-16.65M | $-17.78M | $-16.89M | $-300.00K | $-11.90M | $-9.48M | $-11.24M | $-644.20K | $-6.20M | $-5.26M | $-3.78M | $-9.91M | $-5.27M | $-6.67M | $-7.76M | $-5.05M | $-7.36M | $-7.42M | $-197.42M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 4.24% | 1.30% | 0.87% | 0.90% | 49.18% | 0.84% | 1.59% | 1.02% | 13.74% | 2.15% | 1.55% | 1.45% | 0.39% | 0.55% | 1.07% | - | - | - | - | - |
undefined analysts predict KALV's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than KalVista Pharmaceuticals's previous annual EBITDA (undefined) of $NaN.
KalVista Pharmaceuticals Net Income Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Jul 22 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Oct 19 | Jul 19 | Apr 19 | Jan 19 | Oct 18 | Apr 18 | Jan 18 | Oct 17 | Jul 16 | Apr 16 | Oct 15 | Jul 15 | Apr 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | 2 | 1 | - | - | 1 | 15 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 9 | 12 | 17 | 9 | 8 | 15 | 15 | 19 |
| Net Income | - | - | - | - | - | - | - | - | - | $-29.03M | $-20.04M | $-11.42M | $-10.05M | $-10.43M | $-10.81M | $-6.58M | $-9.29M | $-5.90M | $-7.34M | $-8.53M | $-3.96M | $-3.30M | $1.92M | $-5.23M | $-4.99M | - | - | - | - | - |
| Avg Forecast | $-24.97M | $-32.83M | $-34.67M | $-40.69M | $-38.22M | $-41.99M | $-42.92M | $-42.30M | $-32.95M | $-25.94M | $-6.05M | $-10.87M | $-12.21M | $-10.63M | $-20.78M | $-10.22M | $-8.26M | $-9.71M | $-21.41M | $-5.30M | $-4.53M | $-3.19M | $-8.33M | $-4.43M | $-5.60M | $-6.47M | $-4.29M | $-6.29M | $-6.33M | $-197.56M |
| High Forecast | $-24.97M | $-32.83M | $-34.67M | $-40.69M | $-38.22M | $-31.38M | $-41.11M | $-42.30M | $-32.95M | $-25.94M | $-4.84M | $-8.70M | $-9.77M | $-8.51M | $-20.78M | $-8.18M | $-6.61M | $-7.76M | $-21.41M | $-4.24M | $-3.62M | $-2.55M | $-6.67M | $-3.55M | $-4.48M | $-5.17M | $-3.43M | $-5.04M | $-5.06M | $-158.05M |
| Low Forecast | $-24.97M | $-32.83M | $-34.67M | $-40.69M | $-38.22M | $-49.38M | $-46.53M | $-42.30M | $-32.95M | $-25.94M | $-7.26M | $-13.05M | $-14.66M | $-12.76M | $-20.78M | $-12.26M | $-9.92M | $-11.65M | $-21.41M | $-6.36M | $-5.43M | $-3.82M | $-10.00M | $-5.32M | $-6.72M | $-7.76M | $-5.14M | $-7.55M | $-7.59M | $-237.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.12% | 3.31% | 1.05% | 0.82% | 0.98% | 0.52% | 0.64% | 1.12% | 0.61% | 0.34% | 1.61% | 0.87% | 1.04% | -0.23% | 1.18% | 0.89% | - | - | - | - | - |
KalVista Pharmaceuticals's average Quarter net income forecast for Oct 18 is $-3.19M, with a range of $-3.82M to $-2.55M. KALV's average Quarter net income forecast represents a -266.18% decrease compared to the company's last Quarter net income of $1.92M (Apr 18).
KalVista Pharmaceuticals SG&A Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Jul 22 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Oct 19 | Jul 19 | Apr 19 | Jan 19 | Oct 18 | Apr 18 | Jan 18 | Oct 17 | Jul 16 | Apr 16 | Oct 15 | Jul 15 | Apr 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | 2 | 1 | - | - | 1 | 15 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 9 | 12 | 17 | 9 | 8 | 15 | 15 | 19 |
| SG&A | - | - | - | - | - | - | - | - | - | $10.63M | $8.13M | $6.17M | $3.56M | $3.63M | $3.28M | $3.30M | $3.07M | $3.42M | $3.25M | $3.05M | $2.90M | $2.61M | $1.96M | $2.13M | $2.70M | - | - | - | - | - |
| Avg Forecast | $30.26M | $18.15M | $12.10M | - | $5.23M | $2.53M | $552.99K | - | $4.76M | - | $8.37K | $421.28K | $1.20M | $626.90K | $1.50M | $1.90M | $4.79M | $3.28M | $3.23M | $3.89M | $3.57M | $1.50M | $620.05K | $1.02M | $116.04K | $8.96K | $7.42K | $13.57K | $5.41K | $267.58K |
| High Forecast | $30.26M | $18.15M | $12.10M | - | $5.23M | $2.53M | $552.99K | - | $4.76M | - | $10.05K | $505.54K | $1.20M | $626.90K | $1.50M | $1.90M | $5.75M | $3.28M | $3.23M | $4.66M | $4.29M | $1.80M | $744.05K | $1.22M | $139.25K | $10.74K | $8.91K | $16.29K | $6.49K | $321.09K |
| Low Forecast | $30.26M | $18.15M | $12.10M | - | $5.23M | $2.53M | $552.99K | - | $4.76M | - | $6.70K | $337.02K | $1.20M | $626.90K | $1.50M | $1.90M | $3.83M | $3.28M | $3.23M | $3.11M | $2.86M | $1.20M | $496.04K | $816.08K | $92.83K | $7.16K | $5.94K | $10.86K | $4.33K | $214.06K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | 971.09% | 14.63% | 2.96% | 5.80% | 2.18% | 1.73% | 0.64% | 1.04% | 1.01% | 0.78% | 0.81% | 1.74% | 3.16% | 2.09% | 23.29% | - | - | - | - | - |
KalVista Pharmaceuticals's average Quarter SG&A projection for May 24 is $4.76M, based on 0 Wall Street analysts, with a range of $4.76M to $4.76M. The forecast indicates a -55.20% fall compared to KALV last annual SG&A of $10.63M (Jan 24).
KalVista Pharmaceuticals EPS Forecast
| May 26 | Jan 26 | Oct 25 | Jul 25 | May 25 | Jan 25 | Oct 24 | Jul 24 | May 24 | Jan 24 | Jul 22 | Apr 21 | Jan 21 | Oct 20 | Jul 20 | Apr 20 | Jan 20 | Oct 19 | Jul 19 | Apr 19 | Jan 19 | Oct 18 | Apr 18 | Jan 18 | Oct 17 | Jul 16 | Apr 16 | Oct 15 | Jul 15 | Apr 15 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | - | - | - | 2 | 1 | - | - | 1 | 15 | 14 | 10 | 10 | 7 | 12 | 7 | 6 | 3 | 3 | 6 | 9 | 9 | 12 | 17 | 9 | 8 | 15 | 15 | 19 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.00 | $-0.82 | $-0.49 | $-0.39 | $-0.44 | $-0.36 | $-0.37 | $-0.30 | $-0.11 | $-0.32 | $-0.49 | $-0.06 | $-0.13 | $0.18 | $-0.74 | $-0.40 | - | - | - | - | - |
| Avg Forecast | $-0.54 | $-0.71 | $-0.75 | $-0.88 | $-0.83 | $-0.91 | $-0.93 | $-0.92 | $-0.71 | $-0.75 | $-1.04 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.21 | $-0.21 | $-0.40 | $-0.67 | $-3.08 | $-1.68 | $-4.54 | $-2.03 | $-88.79 |
| High Forecast | $-0.54 | $-0.71 | $-0.75 | $-0.88 | $-0.83 | $-0.68 | $-0.89 | $-0.92 | $-0.71 | $-0.75 | $-1.04 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.17 | $-0.17 | $-0.32 | $-0.54 | $-2.46 | $-1.34 | $-3.63 | $-1.62 | $-71.04 |
| Low Forecast | $-0.54 | $-0.71 | $-0.75 | $-0.88 | $-0.83 | $-1.07 | $-1.01 | $-0.92 | $-0.71 | $-0.75 | $-1.04 | $-0.53 | $-0.60 | $-0.67 | $-0.60 | $-0.65 | $-0.26 | $-0.55 | $-0.62 | $-0.35 | $-0.45 | $-0.25 | $-0.25 | $-0.48 | $-0.80 | $-3.70 | $-2.02 | $-5.45 | $-2.43 | $-106.55 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.00% | 0.79% | 0.92% | 0.65% | 0.66% | 0.60% | 0.57% | 1.15% | 0.20% | 0.52% | 1.41% | 0.13% | 0.62% | -0.86% | 1.85% | 0.60% | - | - | - | - | - |
According to 9 Wall Street analysts, KalVista Pharmaceuticals's projected average Quarter EPS for Oct 18 is $-0.21, with a low estimate of $-0.25 and a high estimate of $-0.17. This represents a -216.67% decrease compared to KALV previous annual EPS of $0.18 (Apr 18).
KalVista Pharmaceuticals Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| KRON | Kronos Bio | $0.94 | $7.63 | 711.70% | Buy |
| GOSS | Gossamer Bio | $0.90 | $3.75 | 316.67% | Buy |
| EWTX | Edgewise Therapeutics | $18.08 | $48.00 | 165.49% | Buy |
| KALV | KalVista Pharmaceuticals | $10.57 | $26.00 | 145.98% | Buy |
| IMCR | Immunocore | $33.90 | $77.43 | 128.41% | Buy |
| REPL | Replimune Group | $11.03 | $24.20 | 119.40% | Buy |
| LRMR | Larimar Therapeutics | $6.81 | $14.50 | 112.92% | Buy |
| SNDX | Syndax Pharmaceuticals | $18.06 | $36.00 | 99.34% | Buy |
| CGEM | Cullinan Oncology | $17.24 | $32.00 | 85.61% | Buy |
| VRDN | Viridian Therapeutics | $21.18 | $37.83 | 78.61% | Buy |
| LYRA | Lyra Therapeutics | $0.28 | $0.50 | 78.57% | Hold |
| COGT | Cogent Biosciences | $10.52 | $18.50 | 75.86% | Buy |
| MRSN | Mersana Therapeutics | $2.04 | $3.00 | 47.06% | Buy |
| CYTK | Cytokinetics | $56.16 | $80.92 | 44.09% | Buy |
| KURA | Kura Oncology | $20.16 | $28.67 | 42.21% | Buy |
| MIRM | Mirum Pharmaceuticals | $40.29 | $54.50 | 35.27% | Buy |
| CRNX | Crinetics Pharmaceuticals | $52.99 | $70.14 | 32.36% | Buy |
| DYN | Dyne Therapeutics | $34.60 | $43.88 | 26.82% | Buy |
| DICE | DICE Therapeutics | $47.55 | $60.00 | 26.18% | Buy |
| KRTX | Karuna Therapeutics | $329.83 | $257.50 | -21.93% | Buy |
KALV Forecast FAQ
Is KalVista Pharmaceuticals a good buy?
Yes, according to 4 Wall Street analysts, KalVista Pharmaceuticals (KALV) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 100.00% of KALV's total ratings.
What is KALV's price target?
KalVista Pharmaceuticals (KALV) average price target is $26 with a range of $20 to $38, implying a 146.21% from its last price of $10.56. The data is based on 4 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will KalVista Pharmaceuticals stock go up soon?
According to Wall Street analysts' prediction for KALV stock, the company can go up by 146.21% (from the last price of $10.56 to the average price target of $26), up by 259.85% based on the highest stock price target, and up by 89.39% based on the lowest stock price target.
Can KalVista Pharmaceuticals stock reach $20?
KALV's average twelve months analyst stock price target of $26 supports the claim that KalVista Pharmaceuticals can reach $20 in the near future.
What is KalVista Pharmaceuticals's current price target trend?
2 Wall Street analysts forecast a $20 price target for KalVista Pharmaceuticals (KALV) this month, up 89.39% from its last price of $10.56. Compared to the last 3 and 12 months, the average price target increased by 89.39% and increased by 89.39%, respectively.
What are KalVista Pharmaceuticals's analysts' financial forecasts?
KALV's analysts financial forecasts for the fiscal year (Apr 2021) are as follows: average revenue is $3.74M (high $3.83M, low $3.66M), average EBITDA is $-43.066M (high $-34.512M, low $-51.619M), average net income is $-54.495M (high $-47.751M, low $-61.238M), average SG&A $3.76M (high $3.84M, low $3.67M), and average EPS is $-2.397 (high $-2.397, low $-2.397).
Did the KALV's actual financial results beat the analysts' financial forecasts?
Based on KalVista Pharmaceuticals's last annual report (Apr 2020), the company's revenue was $12.69M, which missed the average analysts forecast of $18.46M by -31.26%. Apple's EBITDA was $-39.654M, beating the average prediction of $-27.817M by 42.55%. The company's net income was $-29.116M, missing the average estimation of $-49.602M by -41.30%. Apple's SG&A was $13.03M, missing the average forecast of $13.2M by -1.27%. Lastly, the company's EPS was $-1.64, missing the average prediction of $-2.081 by -21.18%. In terms of the last quarterly report (Apr 2020), KalVista Pharmaceuticals's revenue was $3.82M, beating the average analysts' forecast of $1.9M by 101.72%. The company's EBITDA was $-8.345M, missing the average prediction of $-9.913M by -15.82%. KalVista Pharmaceuticals's net income was $-6.584M, missing the average estimation of $-10.22M by -35.58%. The company's SG&A was $3.3M, beating the average forecast of $1.9M by 73.34%. Lastly, the company's EPS was $-0.37, missing the average prediction of $-0.652 by -43.30%